Clinical Trials Browser

INDUSTRY × Lutetium-177 × NET × Clear all

NCT04711135 2026-02-12

NETTER-P

Phase 2 Active not recruiting

11 enrolled 14 charts 2 FDA

CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT05884255 2023-08-09

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Phase 3 Recruiting

EndocrineGastrointestinalNET

Advanced Gastroenteropancreatic Neuroendocrine Tumor